Medincell Stock Climbs 3% and Leads the SBF 120 in a Turbulent Market
The biotech company from Montpellier advances at the opening, going against the grain of a Parisian market weighed down by a resurgence of geopolitical tensions. The stock takes the lead in the broader index, continuing a recovery that began on June 18 following a severe drop post-publication.
The Stock Takes the Lead in the SBF 120 and Attempts to Recover Its Moving Averages
Medincell gains 3.03% to €25.82 in early trading, marking the highest rise in the SBF 120 while the index falls by 1.02%. The session appears challenging for the Parisian market, burdened by a sharp rebound in the VIX (+21.7%, at 20.42) amid ongoing tensions around the Strait of Hormuz. In this defensive context, the biotech benefits from a recovery movement after another negative week (-7.2% over seven days). However, the stock remains below its three moving averages, which limits the extent of the rebound: the MM20 at €26.83 (a gap of -3.76%) is the first hurdle to overcome, while the MM50 and MM200 are nearly at the same level, around €26.00. The RSI at 44 remains neutral, indicating a market without a clear trend for the stock. The contrast is stark with the bottom of the ranking, where Soitec and STMicroelectronics lose nearly 8% and over 6% respectively, in a tense sectoral context on semiconductors. The biotech, disconnected from these issues, plays its own rhythm.
A Rebound that Extends the Digestion of the Annual Accounts Published Last Week
Today's movement continues the rebound that began the previous day, as the market continues to digest the publication of the annual results for 2025/2026 on June 16. The stock had then plunged 13.5% at the opening on June 17, penalized by a net loss amounting to €31.3M, despite a 42% increase in Uzedy royalties to €9.3M. Over three months, the performance remains largely positive, at +27.6%, and the annual gain reaches 52.6%. During this publication on June 16, the company highlighted two levers: the expected growth of Uzedy royalties and the commercial launch of Olanzapine LAI, scheduled for the fourth quarter of 2026. Conversely, the management pointed out a foreseeable increase in operating expenses and the absence of exceptional revenues comparable to last year. In the short term, the dynamics of the stock will depend on its ability to cross the €26 zone where the three moving averages converge.
